What question did this study set out to answer?

To evaluate the association between the apolipoprotein A5 (APOA5) c.553G > T (rs2075291) variant and plasma triglyceride levels in coronary artery disease patients receiving atorvastatin.

January 3, 2019BMC Cardiovascular DisordersOpen Access

A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug

View Full Paper

Ask AI

Bookmark

Why the study?

Elevated plasma triglycerides are a cardiovascular risk predictor in CHD, but the impact of the APOA5 c.553G > T variant on triglyceride levels in CAD patients receiving atorvastatin was unknown.

Does the APOA5 c.553G > T variant affect triglyceride levels in CAD patients receiving atorvastatin?

Key Points

To evaluate the association between the apolipoprotein A5 (APOA5) c.553G > T (rs2075291) variant and plasma triglyceride levels in coronary artery disease patients receiving atorvastatin.
Conducted a case-control study enrolling 608 subjects from the same geographical region.
Genotyped subjects for the APOA5 c.553G > T (G185C, rs2075291) polymorphism and measured lipid profiles during atorvastatin treatment.
Patients carrying the T allele demonstrated significantly lower plasma triglyceride levels compared to GG genotype carriers while receiving atorvastatin therapy (P < 0.001).
Homozygous carriers of the T allele exhibited cholesterol levels of 134 mg/dL, whereas cholesterol levels in GG genotype carriers ranged from 25 to 340 mg/dL (P < 0.001).

Structured PICO

Does the APOA5 c.553G > T variant affect triglyceride levels in CAD patients receiving atorvastatin?

Population

608 subjects, including coronary artery disease (CAD) patients receiving atorvastatin

Intervention

APOA5 c.553G > T (rs2075291) genetic variant (T allele)

Comparator

APOA5 GG allele

Outcome

Plasma triglyceride (TG) levelssurrogate

The APOA5 c.553G > T variant is a significant predictor of hypertriglyceridemia and is associated with reduced TG levels in CAD patients treated with atorvastatin.

Implication

May identify CAD patients with persistent hypertriglyceridemia despite therapy; leaves open whether genotyping improves outcomes.

Abstract

BACKGROUND: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug. METHODS: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the same area was performed. RESULTS: , P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele. The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels. CONCLUSION: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication, atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it could be used as a hallmark for the diagnosis and prognosis of CAD.